JULIO BELARMINO
BOBES GARCIA
Investigador fins a 2022
Instituto de Neurociencias del Principado de Asturias
Oviedo, EspañaPublicacions en col·laboració amb investigadors/es de Instituto de Neurociencias del Principado de Asturias (18)
2024
-
Clinical predictors and psychosocial risk factors of suicide attempt severity
Spanish Journal of Psychiatry and Mental Health
-
The mediating role of reflective functioning in the association between childhood trauma and suicide attempt
Journal of Psychiatric Research, Vol. 171, pp. 30-37
2023
-
Common genetic variants contribute to heritability of age at onset of schizophrenia
Translational Psychiatry, Vol. 13, Núm. 1
-
Correction: Common genetic variants contribute to heritability of age at onset of schizophrenia (Translational Psychiatry, (2023), 13, 1, (201), 10.1038/s41398-023-02508-0)
Translational Psychiatry
-
Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in depressed patients with suicidal behavior: A systematic review
European Psychiatry
2020
-
COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?
Schizophrenia Research, Vol. 223, pp. 192-198
-
Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences
Scientific Reports, Vol. 10, Núm. 1
-
Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample
Journal of global health, Vol. 10, Núm. 2, pp. 020505
-
Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model
European Neuropsychopharmacology, Vol. 33, pp. 158-163
-
Prevalence of Passive Suicidal Ideation in the Early Stage of the Coronavirus Disease 2019 (COVID-19) Pandemic and Lockdown in a Large Spanish Sample
The Journal of clinical psychiatry, Vol. 81, Núm. 6
-
Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene
Schizophrenia Research
2019
-
Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?
Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 9-16
-
Early versus late stage schizophrenia. What markers make the difference?
World Journal of Biological Psychiatry, Vol. 20, Núm. 2, pp. 159-165
-
History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders
European Addiction Research, Vol. 25, Núm. 3, pp. 111-118
-
Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology
Psychiatry Research, Vol. 280
2018
-
Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia
Psychiatry Research, Vol. 269, pp. 688-691
-
Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls
European Psychiatry, Vol. 47, pp. 50-59
2016
-
Biomarcadores sanguíneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia
Revista de Psiquiatria y Salud Mental